Biocon hits 52-week low as Pfizer scraps deal

Tags: Biocon, Companies
Shares of Biocon tumbled by over 6 per cent today, as a drug deal of the biotechnology firm with US-based pharmaceutical giant Pfizer was scrapped.

After plunging as much as 11 per cent to touch a 52-week low of Rs 238 in the intra-day trade on the BSE, Biocon shares recovered some of the losses and settled for the day 6.31 per cent down at Rs 250.80.

At the NSE also, the stock closed at Rs 250.85, down 6.24 per cent.

Earlier in the day, Biocon and Pfizer called off their $ 350 million global alliance to commercialise the Bangalore-based firm's biosimilar versions of insulin and insulin analog products.

"The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently," the two firms said in a joint statement.

The fall in Biocon share price was in sharp contrast to an overall rally in the market, where the barometer index Sensex ended 225.95 points up at 17,813.62.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The current value of the rupee does not merit market intervention

    The rupee, losing 40 paise per month against the dollar since May, is expected to remain under pressure till the calendar runs out on December 31, bef

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Sustainable model for rural sanitation

Prime minister Narendra Modi has promised to build a toilet ...

Zehra Naqvi

How smells evoke strong memories

Remember that time when a passing fragrance transported you to ...

Dharmendra Khandal

Indian zoos need a fresh approach

Recently, when a man jumped in a tiger trench of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture